Cost-Effectiveness of Afatinib, Erlotinib, and Cisplatin/Pemetrexed for First-Line Treatment of Metastatic Egfr-Mutation Positive Non-Small Cell Lung Cancer
Abstract
Authors
J. Ting T. Ho P. Xiang M. Abdel-Sattar A. Sugay L.S. Wilson